A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Pentylenetetrazole (Primary)
- Indications Hypersomnia; Narcolepsy
- Focus Therapeutic Use
- Sponsors Balance Therapeutics
- 01 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 27 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.